ANIMAL HEALTH CERTIFICATE FOR THE MOVEMENT BETWEEN MEMBER STATES OF CONSIGNMENTS OF OOCYTES AND EMBRYOS OF BOVINE ANIMALS COLLECTED OR PRODUCED, PROCESSED AND STORED IN ACCORDANCE WITH REGULATION (EU) 2016/429 AND DELEGATED REGULATION (EU) 2020/686 AFTER 20 APRIL 2021, DISPATCHED BY THE EMBRYO COLLECTION OR PRODUCTION TEAM BY WHICH THE OOCYTES OR EMBRYOS WERE COLLECTED OR PRODUCED (MODEL 'BOV-OOCYTES-EMB-A-INTRA')

EUROPEAN UNION					INTRA
Part I: Description of consignment	I.1	**Consignor** Name Address Country	ISO country code	I.2 **IMSOC reference** I.2a **Local reference** I.3 **Central Competent Authority** I.4 **Local Competent Authority**	**QR CODE**
	I.5	**Consignee** Name Address Country	ISO country code	I.6 **Operator conducting assembly operations independently of an establishment** Name Address Country	Registration No ISO country code
	I.7	**Country of origin**	ISO country code	I.9 **Country of destination**	ISO country code
	I.8	**Region of origin**	Code	I.10 **Region of destination**	Code
	I.11	**Place of dispatch** Name Address Country	Registration/Approval No ISO country code	I.12 **Place of destination** Name Address Country	Registration/Approval No ISO country code
	I.13	**Place of loading**		I.14 **Date and time of departure**	
	I.15	**Means of transport** □ Vessel □ Aircraft □ Railway □ Road vehicle Identification □ Other Document		I.16 **Transporter** Name Address Country I.17 **Accompanying documents** Type Country Commercial document reference	Registration/Authorisation No ISO country code Code ISO country code
	I.18	**Transport conditions**	□ Ambient □ Chilled □ Frozen		
	I.19	**Container number/Seal number** Container No	Seal No		

I.20	**Certified as or for**		
□ Further keeping	□ Slaughter	□ Confined establishment	□ Germinal products
□ Registered equine animal	□ Travelling circus/animal act	□ Exhibition	□ Event or activity near borders
□ Release into the wild	□ Dispatch centre	□ Relaying area/purification centre	□ Ornamental aquaculture establishment
□ Further processing	□ Organic fertilizers and soil improvers	□ Technical use	□ Quarantine or similar establishment
□ Products for human consumption	□ Pollination	□ Live aquatic animals for human consumption	□ Other

I.21	**□ For transit through a third country**	
	Third country	ISO country code
	Exit point	BCP code
	Entry point	BCP code

I.22	**□ For transit through Member State(s)**		**I.23**	**□ For export**	
	Member State	ISO country code		Third country	ISO country code
	Member State	ISO country code		Exit point	BCP code
	Member State	ISO country code			

I.24	**Estimated journey time**	**I.25**	**Journey log**	□ yes	□ no
I.26	**Total number of packages**	**I.27**	**Total quantity**		
I.28	**Total net weight/gross weight (kg)**	**I.29**	**Total space foreseen for the consignment**		

I.30 Description of consignment

CN code	Species	Subspecies/Category	Sex	Identification system	Identification number	Age	Quantity Type
Region of origin		Cold store		Identification mark	Type of packaging		Net weight
Slaughterhouse		Treatment type		Nature of commodity	Number of packages		Batch No
		Date of collection/production		Manufacturing plant	Approval or registration number of plant/establishment/centre	Test	

EUROPEAN UNION **Certificate model BOV-OOCYTES-EMB-A-INTRA**

Part II: Certification

II. Health information

II.a Certificate reference	**II.b IMSOC reference**

I, the undersigned official veterinarian, hereby certify that:

(1)[II.1. The *in vivo* derived embryos of bovine animals described in Part I have been collected, processed and stored, and dispatched by the embryo collection team(2) which

II.1.1. is approved and kept in a register by the competent authority;

II.1.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Part 2 of Annex I to Commission Delegated Regulation (EU) 2020/686.]

(1)[II.1. The oocytes(1)/ *in vitro* produced embryos(1)/ micromanipulated embryos(1) of bovine animals described in Part I have been collected or produced, processed and stored, and dispatched by the embryo production team(2) which

II.1.1. is approved and kept in a register by the competent authority;

II.1.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Parts 2 and 3 of Annex I to Delegated Regulation (EU) 2020/686.]

II.2. The oocytes(1)/ embryos(1) described in Part I are intended for artificial reproduction and were obtained from donor animals which

II.2.1. have been born and remained since birth in the Union, or have entered the Union in accordance with the requirements for entry into the Union;

II.2.2. come from establishments in a Member State or zone thereof, or from establishments under official control by the competent authority in a third country or territory, or a zone thereof

II.2.2.1. free from infection with *Mycobacterium tuberculosis* complex (*M. bovis, M. caprae* and *M. tuberculosis*), and they have never been kept previously in any establishment of a lower health status;

II.2.2.2. free from infection with *Brucella abortus, B. melitensis* and *B. suis* and they have never been kept previously in any establishment of a lower health status;

(1)*either* [II.2.2.3. free from enzootic bovine leukosis and they have never been kept previously in any establishment of a lower health status;]

(1)*or* [II.2.2.3. not free from enzootic bovine leukosis and the official veterinarian responsible for the establishment of origin has certified that there has been no clinical case of enzootic bovine leukosis during a period of at least the preceding 3 years;]

(1)*either* [II.2.2.4. free from infectious bovine rhinotracheitis/infectious pustular vulvovaginitis and they have never been kept previously in any establishment of a lower health status;]

	[(1)*or* [II.2.2.4. not free from infectious bovine rhinotracheitis/infectious pustular vulvovaginitis and the official veterinarian responsible for the establishment of origin has certified that there has been no clinical case of infectious bovine rhinotracheitis/infectious pustular vulvovaginitis during a period of at least the preceding 12 months;]
	II.2.2.5. in which surra (*Trypanosoma evansi*) has not been reported during the 30 day period prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1), and
	(1)*either* [surra has not been reported in the establishments during the last 2 years prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1);]
	(1)*or* [surra has been reported in the establishments during the last 2 years prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1) and following the last outbreak the establishments have remained under movement restrictions until – the infected animals have been removed from the establishment, and – the remaining animals on the establishment have been subjected to a test for surra (*Trypanosoma evansi*) with one of the diagnostic methods provided for in Part 3 of Annex I to Commission Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken at least 6 months after the infected animals have been removed from the establishment;]
	II.2.3. were examined by the team veterinarian or a team member and did not show symptoms or clinical signs of transmissible animal diseases on the day of collection(1)/ production(1) of the oocytes(1)/ embryos(1);
	II.2.4. are individually identified as provided for in Article 38 of Commission Delegated Regulation (EU) 2019/2035;
	II.2.5. for a period of at least 30 days prior to the date of first collection(1)/ production(1) of the oocytes(1)/ embryos(1) and during the collection period
	▶(1) II.2.5.1. were kept on establishments not situated in a restricted zone established due to the occurrence of foot-and-mouth disease, infection with rinderpest virus, infection with Rift Valley fever virus, contagious bovine pleuropneumonia or lumpy skin disease or of an emerging disease relevant for bovine animals; ◀
	II.2.5.2. were kept on a single establishment where infection with *Brucella abortus, B. melitensis* and *B. suis*, infection with *Mycobacterium tuberculosis* complex (*M. bovis, M. caprae and M. tuberculosis*), rabies, anthrax, surra *(Trypanosoma evansi),* enzootic bovine leukosis, infectious bovine rhinotracheitis/infectious pustular vulvovaginitis, bovine viral diarrhoea, infection with epizootic haemorrhagic disease virus and infection with bluetongue virus (serotypes 1-24) have not been reported;

II.2.5.3. were not in contact with animals from establishments situated in a restricted zone due to the occurrence of diseases referred to in point II.2.5.1. or from establishments which do not meet the conditions referred to in point II.2.5.2.;

II.2.5.4. were not used for natural breeding;

II.2.6. comply with the following conditions as regards foot-and-mouth disease

II.2.6.1. they come from establishments

- situated in an area where foot-and-mouth disease has not been reported within a 10-km radius centred on the establishment for a period of at least 30 days immediately prior to the date of collection of the oocytes(1)/ embryos(1);
- in which foot-and-mouth disease has not been reported during a period of at least 3 months immediately prior to the date of collection of the oocytes(1)/ embryos(1);

(1)*either* [II.2.6.2. they were not vaccinated against foot-and-mouth disease;]

(1)(3)*or* [II.2.6.2. they were vaccinated against foot-and-mouth disease during the period of 12 months prior to the date of collection or production of the embryos and

II.2.6.2.1. have not been vaccinated against foot-and-mouth disease within the period of at least 30 days immediately prior to the date of collection of the embryos;

II.2.6.2.2. the semen used for fertilisation was collected from a male donor that complies with the conditions set out in point 1(b) or the semen complies with the conditions set out in point 2 of Chapter I of Part 5 of Annex II to Delegated Regulation (EU) 2020/686;

II.2.6.2.3. prior to freezing, the embryos have been subjected to trypsin washing carried out in accordance with the recommendations of the IETS Manual(4);

II.2.6.2.4. the embryos were stored deep frozen for a period of at least 30 days from the date of collection, and during this period the donor animal has not shown clinical signs of foot-and-mouth disease;]

(1)(5)[II.2.7. comply with at least one of the following conditions as regards infection with bluetongue virus (serotypes 1-24):

(1)*either* [II.2.7.1. they have been kept for a period of at least 60 days prior to and during collection of the oocytes in a third country, territory or zone thereof free from infection with bluetongue virus (serotypes 1-24) where no case of infection with bluetongue virus (serotypes 1-24) has been confirmed during the last 24 months in the targeted animal population;]

	(1) *and/or* [II.2.7.2. they have been kept in a seasonally disease-free zone, during the seasonally disease-free period, for a period of at least 60 days prior to and during collection of the oocytes, in a third country, territory or zone thereof with an approved eradication programme against infection with bluetongue virus (serotypes 1-24);]
	(1) *and/or* [II.2.7.3. they have been kept in a seasonally disease-free zone, during the seasonally disease-free period, for a period of at least 60 days prior to and during collection of the oocytes, in a third country, territory or zone thereof where the competent authority of the place of origin of the consignment of oocytes(1)/ *in vitro* produced embryos(1) has obtained the prior written consent of the competent authority of the Member State of destination to the conditions for establishment of that seasonally disease-free zone and to accept the consignment of oocytes(1)/ *in vitro* produced embryos(1);]
	(1) *and/or* [II.2.7.4. they have been kept in a vector-protected establishment for a period of at least 60 days prior to and during collection of the oocytes;]
	(1) *and/or* [II.2.7.5. they have been subjected to a serological test to detect antibodies to the bluetongue virus serogroup 1-24, with negative results, between 28 and 60 days from the date of each collection of the oocytes;]
	(1) *and/or* [II.2.7.6. they have been subjected to an agent identification test for bluetongue virus (serotypes 1-24), with negative results, on blood sample taken on the day of collection of the oocytes;]]
	(1)(5)[II.2.8. comply with at least one of the following conditions as regards infection with epizootic haemorrhagic disease virus (serotypes 1-7) (EHDV 1-7):
	(1) *either* [II.2.8.1. they have been kept for a period of at least 60 days prior to and during collection of the oocytes in a third country, territory or zone thereof where EHDV 1-7 has not been reported for a period of at least the preceding 2 years within a radius of 150 km of the establishment;]
	(1) *and/or* [II.2.8.2. they have been kept in a vector-protected establishment for a period of at least 60 days prior to and during collection of the oocytes;]
	(1) *and/or* [II.2.8.3. were resident in the exporting country in which according to official findings the following serotypes of EHDV exist: …… and have been subjected with negative results in each case to the following tests carried out in an official laboratory:
	(1) *either* [II.2.8.3.1. a serological test to detect antibodies to EHDV 1-7, with negative results, on blood sample taken between 28 and 60 days from the date of the collection of the oocytes;]]
	(1) *and/or* [II.2.8.3.2. an agent identification test for EHDV 1-7, with negative results, on blood sample taken on the day of collection of the oocytes.]]]
	(1)(5)[II.2.9. comply with animal health requirements laid down in Chapter III of Part 1 of Annex II to Delegated Regulation (EU) 2020/686.]

II.3. The oocytes[1]/ embryos[1] described in Part I

II.3.1. has been collected, processed and stored in accordance with animal health requirements set out in Part 2[1]/Part 3[1]/Part 4[1]/Part 5[1] and Part 6 of Annex III to Delegated Regulation (EU) 2020/686;

II.3.2. are placed in straws or other packages on which the mark is applied in accordance with requirements provided for in Article 10 of Delegated Regulation (EU) 2020/686 and that mark is indicated in Box I.30;

II.3.3. are transported in a container which:

II.3.3.1. was sealed and numbered prior to the dispatch by the embryo collection or production team under responsibility of the team veterinarian, or by an official veterinarian, and the seal bears the number as indicated in Box I.19;

II.3.3.2. has been cleaned and either disinfected or sterilised before use, or is single-use container;

[1][6][II.3.3.3. has been filled in with the cryogenic agent which not have been previously used for other products;]

[1][7][II.3.4. are placed in straws or other packages which are securely and hermetically sealed;

II.3.5. are transported in a container where they are separated from each other by physical compartments or by being placed in secondary protective bags.]

[1][8][II.4. The *in vivo* derived embryos[1]/ *in vitro* produced embryos[1]/ micromanipulated embryos[1] described in Part I were conceived by artificial insemination using semen coming from a semen collection centre, germinal product processing establishment or germinal product storage centre approved for the collection, processing and/or storage of semen by the competent authority of a Member State or by the competent authority of a third country, territory or zone thereof listed in Annex IX to Commission Implementing Regulation (EU) 2021/404.]

[1][9][II.5. The following antibiotic or mixture of antibiotics[10] has been added to the collection, processing, washing or storage media: ……]

Notes

This animal health certificate shall be completed according to the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.

Part I:

Box reference I.11: "*Place of dispatch":* Indicate the unique approval number and the name and address of the embryo collection or production team of dispatch of the consignment of oocytes or embryos.

Box reference I.12: "*Place of destination":* Indicate the address and unique registration or approval number of the establishment of destination of the consignment of oocytes or embryos.

Box reference I.19:	Seal number shall be indicated.
Box reference I.26:	Total number of packages shall correspond to the number of containers.
►(9) Box reference I.30:	"*Species*": Select amongst "*Bos taurus*", "*Bison bison*" or "*Bubalus bubalis*" as appropriate.
	"*Type*" : Specify if oocytes, in vivo derived embryos, in vitro produced embryos or micromanipulated embryos.
	"*Identification number*": Indicate the identification number of each donor animal.
	"*Identification mark*": Indicate the mark on the straw or other packages where oocytes or embryos of the consignment are placed.
	"*Date of collection/production*" : Indicate the date on which oocytes or embryos of the consignment were collected or produced.
	"*Approval or registration number of plant/establishment/centre*" : Indicate the unique approval number of the embryo collection or production team by which the oocytes or embryos were collected or produced.
	"*Quantity*": Indicate the number of straws or other packages with the same mark.
	"*Test*": Indicate for BTV-test: II.2.7.5. and/or II.2.7.6., and/or for EHD-test: II.2.8.3.1. and/or II.2.8.3.2., if relevant.◄

Part II:

(1) Delete if not applicable.

(2) Only embryo collection or production teams approved by the competent authority and included in the register referred to in Article 101(1)(b) of Regulation (EU) 2016/429 and Article 7 of Delegated Regulation (EU) 2020/686.

(3) Option available only for the consignment of *in vivo* derived embryos.

(4) Manual of the International Embryo Transfer Society — A procedural guide and general information for the use of embryo transfer technology emphasising sanitary procedures, published by the International Embryo Transfer Society, 1 111 North Dunlap Avenue, Savoy, Illinois 61 874 USA (http://www.iets.org/).

(5) Applicable for the consignment of oocytes and *in vitro* produced embryos.

(6) Applicable for frozen oocytes or embryos.

(7) Applicable for the consignment where in one container oocytes, *in vivo* derived embryos, *in vitro* produced embryos and micromanipulated embryos of bovine animals are placed and transported.

(8) Does not apply to oocytes.

(9) Mandatory attestation in case antibiotics were added.

(10) Insert the name(s) of the antibiotic(s) added and its(their) concentration.

Official veterinarian

Name (in capital letters)	Qualification and title
Local Control Unit name	Local Control Unit code
Date	
Stamp	Signature